Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Patent
1996-10-29
1999-11-09
Krass, Frederick
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
5147721, 5147725, 5147726, 514781, 514969, 514970, 514777, A61K 4710, A61K 4738, A61K 970
Patent
active
059816058
DESCRIPTION:
BRIEF SUMMARY
This application concerns a matrix-forming and skin-adhesive, anti-evaporant gel for local treatment of skin diseases, for both primary and secondary prophylactic treatment of wounds, and for skin disinfection or the like in both humans and animals. More precisely, the invention relates to a gel characterized by containing lower alkanol in a concentration of more than 90% and by containing a gelling agent, such as ethyl(hydroxyethyl)cellulose or another suitable gelling agent, and possible additives, whereby the gel can be applied to the skin efficiently, easily, and without complications.
BACKGROUND
Infectious skin diseases, both microbial and parasitic, are widespread. Some examples of skin diseases are viral skin infections caused by, for example, Herpes simplex virus or Varicellae Zoster virus, bacterial skin infections caused by, for example, Staphylococcus aureus, fungal infections caused by, for example, Trichophyton rubrum, for eliminating skin parasites, such as Sarcoptes scabiei var. hominis. The virus infection, Herpes simplex, alone occurs with approximately 100 million new cases per year.
Herpes simplex is caused by Herpes simplex virus (HSV). This virus occurs in two antigenically different types, type 1 and type 2. Herpes on the lips and around the mouth (Herpes labialis) is usually caused by type 1; most incidences of Herpes on and around the genitals (Herpes genitalis) are caused by type 2.
The first infection with HSV (primary infection) varies symptomatologically. Usually it occurs during childhood. At this first infection, HSV-DNA is incorporated into the cells. Intermittently, virus proliferation occurs, resulting in Herpes outbreaks from this incorporated HSV-DNA (these outbreaks are called secondary infections). Most Herpes outbreaks in adults are secondary, where the infection flares up due to reduced resistance, febrile diseases (e.g. Pneumonia), traumas, or the effects of cold, heat, or light.
The outbreak starts with flushing, swelling, itching, and pain in the infected area followed by necrosis and a suppurative ulceration which is the most troublesome symptom. A spontaneous healing of the wounds will occur in approximately 10 to 14 days.
The outbreak of Herpes genitalis--mentioned above--is identical to that of Herpes labialis except for the fact that Herpes genitalis is located on and around the genitals.
The number of therapeutics for, for example, HSV skin infections is very limited, and the present antiviral chemotherapy has not convincingly been proved efficient. Furthermore, there exists a few products for advancing the healing of established HSV-wounds and inhibition of further outbreaks. However, none of these products have a convincing effect.
Bacterial infections such as pimples, isolated or in connection with Acne vulgaris, are examples of other skin diseases for which adequate treatments are not currently available. In Acne it is currently believed that lipolysis of triglycerides by Propionibacterium acnes releases fatty acids; it is thought that these fatty acids are capable of eliciting an inflammatory process in the follicle wall, which may then rupture. Discharge of the follicular content leads to perifollicular inflammation. Benzoyl peroxide, which is currently used for-treating acne, has a mode of action dependent upon its broad-spectrum antimicrobial effect on both primary inflammation and on secondary infection. Current treatments based on benzoyl peroxide have inherent problems, including lack of efficacy and adverse reactions such as erythema, burning and desquamation of the skin.
From the literature it is known to use alcohol as disinfectant against, for example, virus including HSV--see, for example, R. Tyler; Journal of Hospital Infection (8: 22-29; 1987). When using alcohols as normal liquids a poor and very brief effect is achieved due to the very rapid evaporation of the alcohols. Also the use of alcohols at concentrations below 90% by weight gives inadequate results.
Furthermore, Moldenhauer, in Zbl. Bakr. Hyg., I Abt. Orig. B 179, 544-554 (1984)
REFERENCES:
patent: 3016328 (1962-01-01), Pepper et al.
patent: 4247547 (1981-01-01), Marks
patent: 4590214 (1986-05-01), Zamore
patent: 4593048 (1986-06-01), Sato et al.
patent: 4671955 (1987-06-01), Palinczar
patent: 4849455 (1989-07-01), Eggers
patent: 4992475 (1991-02-01), Marcel
patent: 5013545 (1991-05-01), Blackman et al.
patent: 5098717 (1992-03-01), Blackman
patent: 5145663 (1992-09-01), Simmons
patent: 5288486 (1994-02-01), White
patent: 5331012 (1994-07-01), Riddick et al.
Seelig and Gould, "Osmosis As an Important Factor in the Action of Antiseptics", manuscript presented to Western Surgical Association Dec. 10, 1910, pp.262-270.
Harrington, "The Germicidal Action of Alcohol", Boston Medical and Surgical Journal (1903) pp. 548-552.
Christiansen, "Zur Theorie und Praxis der Alkoholdesinfektion", Aus dem Institut fur allgemeine Pathologie in Kopenhagen (1918) pp.275-305.
H.E. Morton, "Alcohols" in Disinfection, Sterilization and Preservation, 2.sup.nd Ed., pp. 301-318, 1997.
J.B. Thomsen, "Concentration/Formulation Experiments" --Declaration, Aug., 1998.
S. Mogensen, Blackman et al. --Declaration, Sep., 1998.
H. K. Andersen, In Vitro Antiviral--Declaration, Sep., 1998.
F.T. Black, Clinical Trial--Declaration, Sep., 1998.
Microbiology: An Introduction, Fifth Edition, Tortora, Funke and Case, Benjamin Cummings Publishing Co., 1994.
"A Surface Test for Virucidal Activity of Disinfectants: Preliminary Study with Herpes Virus", R. Tyler et al, Journal of Hospital Infection (1987) 9, 22-29.
"Quantitative Evaluation of the Effects of Disinfectants Against Viruses in Suspension Experiments", D. Moldenhauer, pp. 544-554 (1984).
"In Vitro Virucidal Activity by Components of a Topical Film-Forming Medication", B. Rodu et al, J. Oral Pathol 1988, 17:324-326.
Chem. Abstract, 90:76562r (1979).
M.o slashed.ller Jens Christian
Thomsen John Brown
Krass Frederick
Thomsen John Brown
LandOfFree
Gel for treatment of skin diseases and for disinfection of the s does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gel for treatment of skin diseases and for disinfection of the s, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gel for treatment of skin diseases and for disinfection of the s will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1456899